Eosinophilia in mast cell disease.

[1]  D. Dorward,et al.  Middleton’s Allergy: Principles and Practice , 2013 .

[2]  W. Busse,et al.  Middleton's Allergy: Principles and Practice , 2013 .

[3]  C. Akin,et al.  Mastocytosis: update on pharmacotherapy and future directions , 2013, Expert opinion on pharmacotherapy.

[4]  D. Broide,et al.  Anti-IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis. , 2013, The Journal of allergy and clinical immunology.

[5]  I. Bachelet,et al.  Interacting mast cells and eosinophils acquire an enhanced activation state in vitro , 2013, Allergy.

[6]  Ian D Pavord,et al.  Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial , 2012, The Lancet.

[7]  J. Gotlib,et al.  Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders. , 2012, Seminars in hematology.

[8]  J. Butterfield,et al.  Use of pegylated interferon in hypereosinophilic syndrome. , 2012, Leukemia research.

[9]  H. Vestergaard,et al.  Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. , 2011, The Journal of molecular diagnostics : JMD.

[10]  F. Levi-Schaffer,et al.  Physical interactions between mast cells and eosinophils: a novel mechanism enhancing eosinophil survival in vitro , 2011, Allergy.

[11]  P. Valent,et al.  How I treat patients with advanced systemic mastocytosis. , 2010, Blood.

[12]  K. Stringer,et al.  Involvement of mast cells in eosinophilic esophagitis. , 2010, The Journal of allergy and clinical immunology.

[13]  J. Sheikh,et al.  Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. , 2009, The Journal of allergy and clinical immunology.

[14]  A. Tefferi,et al.  Prognostically relevant breakdown of 123 patients with systemic mastocytosis associated with other myeloid malignancies. , 2009, Blood.

[15]  J. Parkin,et al.  Treatment of patients with the hypereosinophilic syndrome with mepolizumab. , 2008, The New England journal of medicine.

[16]  M. Fay,et al.  KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities. , 2007, The Journal of allergy and clinical immunology.

[17]  D. Metcalfe,et al.  Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. , 2007, The Journal of allergy and clinical immunology.

[18]  E. Cutz,et al.  Activated Mucosal Mast Cells Differentiate Eosinophilic (Allergic) Esophagitis From Gastroesophageal Reflux Disease , 2007, Journal of pediatric gastroenterology and nutrition.

[19]  O. Haas,et al.  Systemic mastocytosis (SM) associated with chronic eosinophilic leukemia (SM-CEL): detection of FIP1L1/PDGFRalpha, classification by WHO criteria, and response to therapy with imatinib. , 2006, Leukemia research.

[20]  T. Nutman,et al.  Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA‐positive hypereosinophilic syndrome , 2006, British journal of haematology.

[21]  E. Bargagli,et al.  Tryptase concentrations in bronchoalveolar lavage from patients with chronic eosinophilic pneumonia. , 2005, Clinical science.

[22]  K. Sotlar,et al.  Mastocytosis: Pathology, genetics, and current options for therapy , 2005, Leukemia & lymphoma.

[23]  D. Metcalfe,et al.  The biology of Kit in disease and the application of pharmacogenetics. , 2004, The Journal of allergy and clinical immunology.

[24]  D. Metcalfe,et al.  Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. , 2004, Blood.

[25]  B. Longley,et al.  Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. , 2003, Experimental hematology.

[26]  D. Gilliland,et al.  Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. , 2003, Blood.

[27]  Peter Marynen,et al.  A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. , 2003, The New England journal of medicine.

[28]  P. Lipsky,et al.  Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. , 2002, Blood.

[29]  K. Lennert,et al.  Diagnostic criteria and classification of mastocytosis: a consensus proposal. , 2001, Leukemia research.

[30]  L. Scott,et al.  Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. , 2000, Experimental Hematology.

[31]  P. Anderson.  Clinical Immunology: Principles and Practice , 1996 .

[32]  G. Rasp,et al.  Tryptase in nasal fluid is a useful marker of allergic rhinitis , 1993, Allergy.

[33]  H. Kluin-Nelemans,et al.  Response to interferon alfa-2b in a patient with systemic mastocytosis. , 1992, The New England journal of medicine.

[34]  W. Busse,et al.  Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with increased airway obstruction. , 1991, The American review of respiratory disease.

[35]  D. Manachino,et al.  [Eosinophils and eosinophilia]. , 1989, Giornale di clinica medica.

[36]  P. Weller,et al.  75 – Eosinophilia and Eosinophil-Related Disorders , 2014 .

[37]  T. Casale,et al.  Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. , 2003, The Journal of allergy and clinical immunology.